SCHEMBL5323929

SCHEMBL5323929

CCC(CCCC(N)=O)C(N)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.45
ALOX15 P16050 1/20 0.45
BLM P54132 1/20 0.45
PMP22 Q01453 1/20 0.45
SLC7A5 Q01650 1/20 0.37
DDAH1 O94760 3/20 0.37
NOS1 P29475 3/20 0.37
CA2 P00918 2/20 0.35
MAPK1 P28482 1/20 0.35
FOLH1 Q04609 1/20 0.35
SLC1A2 P43004 3/20 0.34
SLC1A1 P43005 3/20 0.34
SLC1A3 P43003 2/20 0.34
CA1 P00915 1/20 0.34
LTA4H P09960 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ENPEP Q07075 2/20 0.33
GRIK1 P39086 1/20 0.33
GRIK2 Q13002 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5322830 0.90 ALOX15 (0.52) KMT2AALOX15BLMPMP22SLC7A5
SCHEMBL5320858 0.87 KMT2A (0.44) KMT2AALOX15BLMPMP22SLC7A5
SCHEMBL29634861 0.84 CA2 (0.52) SLC7A5CA2MAPK1SLC1A2SLC1A1
SCHEMBL4774070 0.84 CA2 (0.52) SLC7A5CA2MAPK1SLC1A2SLC1A1
SCHEMBL27637001 0.84 CA2 (0.52) SLC7A5CA2MAPK1SLC1A2SLC1A1
SCHEMBL21054367 0.82 GSR (0.45) SLC7A5CA2MAPK1SLC1A2SLC1A1
SCHEMBL21054364 0.82 GSR (0.45) SLC7A5CA2MAPK1SLC1A2SLC1A1
SCHEMBL5321316 0.81 GSR (0.53) SLC7A5FOLH1SLC1A2SLC1A1GRIK1
SCHEMBL7055852 0.79 CHRM1 (0.46) SLC7A5CA2MAPK1SLC1A2SLC1A1
SCHEMBL5319461 0.79 GSR (0.52) KMT2AALOX15FOLH1ALDH1A1GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 KMT2A 3586/4885ALOX15 4182/4885BLM 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.